Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
BeOne Medicines Ltd has a consensus price target of $325.56 based on the ratings of 9 analysts. The high is $350 issued by Guggenheim on May 8, 2025. The low is $311 issued by RBC Capital on June 27, 2025. The 3 most-recent analyst ratings were released by Morgan Stanley, JP Morgan, and RBC Capital on June 27, 2025, respectively. With an average price target of $320.67 between Morgan Stanley, JP Morgan, and RBC Capital, there's an implied 30.88% upside for BeOne Medicines Ltd from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/27/2025 | Buy Now | 34.69% | Morgan Stanley | Sean Laaman72% | $313 → $330 | Maintains | Overweight | Get Alert |
06/27/2025 | Buy Now | 31.02% | JP Morgan | Jessica Fye67% | $317 → $321 | Maintains | Overweight | Get Alert |
06/27/2025 | Buy Now | 26.94% | RBC Capital | Leonid Timashev40% | $311 → $311 | Reiterates | Outperform → Outperform | Get Alert |
05/08/2025 | Buy Now | 26.94% | RBC Capital | Gregory Renza51% | $312 → $311 | Maintains | Outperform | Get Alert |
05/08/2025 | Buy Now | 42.86% | Guggenheim | Michael Schmidt66% | $348 → $350 | Maintains | Buy | Get Alert |
04/28/2025 | Buy Now | 27.35% | RBC Capital | Gregory Renza51% | $312 → $312 | Reiterates | Outperform → Outperform | Get Alert |
04/24/2025 | Buy Now | 36.33% | TD Securities | Yaron Werber37% | $334 → $334 | Reiterates | Buy → Buy | Get Alert |
04/21/2025 | Buy Now | 29.39% | JP Morgan | Jessica Fye67% | $311 → $317 | Maintains | Overweight | Get Alert |
04/16/2025 | Buy Now | — | Guggenheim | Michael Schmidt66% | — | Reiterates | Buy → Buy | Get Alert |
04/10/2025 | Buy Now | 42.04% | Guggenheim | Michael Schmidt66% | $348 → $348 | Reiterates | Buy → Buy | Get Alert |
04/07/2025 | Buy Now | 27.35% | RBC Capital | Greg Renza65% | → $312 | Initiates | → Outperform | Get Alert |
02/28/2025 | Buy Now | 27.76% | Macquarie | Tony Ren13% | $259 → $313 | Maintains | Outperform | Get Alert |
02/28/2025 | Buy Now | 42.04% | Citizens Capital Markets | Matthew Carletti84% | $288 → $348 | Maintains | Market Outperform | Get Alert |
The latest price target for BeOne Medicines (NASDAQ:ONC) was reported by Morgan Stanley on June 27, 2025. The analyst firm set a price target for $330.00 expecting ONC to rise to within 12 months (a possible 34.69% upside). 13 analyst firms have reported ratings in the last year.
The latest analyst rating for BeOne Medicines (NASDAQ:ONC) was provided by Morgan Stanley, and BeOne Medicines maintained their overweight rating.
There is no last upgrade for BeOne Medicines
There is no last downgrade for BeOne Medicines.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BeOne Medicines, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BeOne Medicines was filed on June 27, 2025 so you should expect the next rating to be made available sometime around June 27, 2026.
While ratings are subjective and will change, the latest BeOne Medicines (ONC) rating was a maintained with a price target of $313.00 to $330.00. The current price BeOne Medicines (ONC) is trading at is $245.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.